In Documents on Pain Drug Celebrex, Signs of Doubt and Deception

By Ron Hiram:The U.S. Patent & Trademark Office has granted a reissue patent for Pfizer's (PFE) pain drug, Celebrex, extending the drug's patent protection by 18 months. [1] The patent extension will prevent cheap generic versions from entering the market and pave the way for continued growth in the drug's sales till 2015 end.

By Ron Hiram:The U.S. Patent & Trademark Office has granted a reissue patent for Pfizer's (PFE) pain drug, Celebrex, extending the drug's patent protection by 18 months. [1] The patent extension will prevent cheap generic versions from entering the market and pave the way for continued growth in the drug's sales till 2015 end.

By Brian L. Wilson:Pfizer (PFE) disappointed the street a bit on Tuesday morning with the financial data found in its Q4 report, which represent the first results we'll see of the "crash landing" the company went through with the expiration of the famous statin Lipitor. The drug was worth roughly $10-12 billion every year in sales.

By Vatalyst: Pfizer (PFE) has found a way out of having to go to court against Brigham Young University regarding the issue of royalties allegedly wrongly withheld from the revenue of the drug Celebrex. Celebrex is a pain reliever that has been extremely successful since its entering the market. Brigham Young University was suing Pfizer because it felt that it had been cheated out of billions of dollars in royalties.

The Burrill Report submits: By Michael FitzhughPfizer (PFE), the self-proclaimed “world’s largest research-based pharmaceutical company,” will pare nearly $1.5 billion from its 2012 research and development budget as it steps up its dependence on external partnerships to supply both new innovations and cost savings.

Pfizer said the U.S.

Pharmalot submits: In the latest example of how Pfizer (PFE) is trying to become a Hollywood-like conglomerate, the drugmaker has agreed to pay $3.6 billion to buy King Pharmaceuticals (KG), which sells various pain medications.

Douglas Cress submits:By vandersonWe’ve heard of drugs underperforming in clinical trials, but is it possible for a drug to over-perform? A major pharmaceutical company halted clinical trials of an experimental osteoarthritis drug in June because the drug supposedly worked too well.